loader
Please Wait
Applying Filters...

Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about E7386, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    E7386

    DEVELOPMENTS

    PharmaCompass

    Bora Pharmaceuticals- Making success more certain.

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    2D Structure
    1. Also known as: E-7386, 1799824-08-0, E7386, I0dx1fg55y, (6s,9as)-n-benzyl-8-[[6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl]methyl]-6-[(2-fluoro-4-hydroxyphenyl)methyl]-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazine-1-carboxamide, (6s,9as)-2-allyl-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxohexahydro-2h-pyrazino(2,1-c)(1,2,4)triazine-1(6h)-carboxamide
    Molecular Formula
    C39H48FN9O4
    Molecular Weight
    725.9  g/mol
    InChI Key
    ZGNKNLOBYFTGRG-GIWKVKTRSA-N
    FDA UNII
    I0DX1FG55Y
    CBP/beta-catenin Modulator E7386 is an orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (6S,9aS)-N-benzyl-8-[[6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl]methyl]-6-[(2-fluoro-4-hydroxyphenyl)methyl]-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazine-1-carboxamide
    2.1.2 InChI
    InChI=1S/C39H48FN9O4/c1-3-15-47-27-37(51)48-34(20-29-13-14-32(50)21-33(29)40)38(52)46(26-36(48)49(47)39(53)41-22-28-9-6-5-7-10-28)23-30-11-8-12-35(42-30)45-24-31(25-45)44-18-16-43(4-2)17-19-44/h3,5-14,21,31,34,36,50H,1,4,15-20,22-27H2,2H3,(H,41,53)/t34-,36-/m0/s1
    2.1.3 InChI Key
    ZGNKNLOBYFTGRG-GIWKVKTRSA-N
    2.1.4 Canonical SMILES
    CCN1CCN(CC1)C2CN(C2)C3=CC=CC(=N3)CN4CC5N(C(C4=O)CC6=C(C=C(C=C6)O)F)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C
    2.1.5 Isomeric SMILES
    CCN1CCN(CC1)C2CN(C2)C3=CC=CC(=N3)CN4C[C@H]5N([C@H](C4=O)CC6=C(C=C(C=C6)O)F)C(=O)CN(N5C(=O)NCC7=CC=CC=C7)CC=C
    2.2 Other Identifiers
    2.2.1 UNII
    I0DX1FG55Y
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (6s,9as)-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino(2,1-c)(1,2,4)triazine-1-carboxamide

    2. E-7386

    3. E7386 Compound

    2.3.2 Depositor-Supplied Synonyms

    1. E-7386

    2. 1799824-08-0

    3. E7386

    4. I0dx1fg55y

    5. (6s,9as)-n-benzyl-8-[[6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl]methyl]-6-[(2-fluoro-4-hydroxyphenyl)methyl]-4,7-dioxo-2-prop-2-enyl-3,6,9,9a-tetrahydropyrazino[2,1-c][1,2,4]triazine-1-carboxamide

    6. (6s,9as)-2-allyl-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxohexahydro-2h-pyrazino(2,1-c)(1,2,4)triazine-1(6h)-carboxamide

    7. (6s,9as)-8-((6-(3-(4-ethyl-1-piperazinyl)-1-azetidinyl)-2-pyridinyl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)hexahydro-4,7-dioxo-n-(phenylmethyl)-2-(2-propen-1-yl)-2h-pyrazino(2,1-c)(1,2,4)triazine-1(6h)-carboxamide

    8. 2h-pyrazino(2,1-c)(1,2,4)triazine-1(6h)-carboxamide, 8-((6-(3-(4-ethyl-1-piperazinyl)-1-azetidinyl)-2-pyridinyl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)hexahydro-4,7-dioxo-n-(phenylmethyl)-2-(2-propen-1-yl)-, (6s,9as)-

    9. (6s,9as)-2-allyl-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxohexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide

    10. Chembl4297491

    11. Schembl16822549

    12. Nsc820052

    13. Nsc-820052

    14. Hy-111386

    15. Cs-0040308

    16. (6s,9as)-2-allyl-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxooctahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide

    17. (6s,9as)-n-benzyl-8-((6-(3-(4-ethylpiperazin-1-yl)azetidin-1-yl)pyridin-2-yl)methyl)-6-((2-fluoro-4-hydroxyphenyl)methyl)-4,7-dioxo-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide

    2.4 Create Date
    2015-07-06
    3 Chemical and Physical Properties
    Molecular Weight 725.9 g/mol
    Molecular Formula C39H48FN9O4
    XLogP33.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count10
    Rotatable Bond Count11
    Exact Mass725.38132921 g/mol
    Monoisotopic Mass725.38132921 g/mol
    Topological Polar Surface Area119 Ų
    Heavy Atom Count53
    Formal Charge0
    Complexity1280
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    Post Enquiry
    POST ENQUIRY